Novel Agent Moves Into Ovarian Cancer Combinations (fosbretabulin tromethamine)

Novel Agent Moves Into Ovarian Cancer Combinations

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer. 

 

A clinical trial is looking to develop new therapeutic options for women with advanced, recurrent, platinum-resistant ovarian cancer by using a multipronged attack on the tumor vasculature network.

The novel agent fosbretabulin tromethamine is being combined with Avastin (bevacizumab) and physician’s choice of either paclitaxel or pegylated liposomal doxorubicin in the experimental arm of the phase 2/3 FOCUS study (NCT02641639). The regimen will be compared with Avastin plus chemotherapy, which is one option for this patient population.....